CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada • Toronto Stock Exchange • TSX:CPH • CA17253X1050
14.59 CAD
+0.19 (+1.32%)
Last: Feb 9, 2026, 07:00 PM
Overall CPH gets a fundamental rating of 7 out of 10. We evaluated CPH against 33 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making CPH a very profitable company, without any liquidiy or solvency issues. CPH is growing strongly while it is still valued neutral. This is a good combination! These ratings would make CPH suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
- CPH had positive earnings in the past year.
- In the past year CPH had a positive cash flow from operations.
- In the past 5 years CPH has always been profitable.
- In the past 5 years CPH always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 11.77%, CPH belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
- CPH has a better Return On Equity (15.23%) than 87.88% of its industry peers.
- With an excellent Return On Invested Capital value of 7.23%, CPH belongs to the best of the industry, outperforming 87.88% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
- CPH has a Profit Margin of 34.68%. This is amongst the best in the industry. CPH outperforms 100.00% of its industry peers.
- CPH's Profit Margin has improved in the last couple of years.
- The Operating Margin of CPH (25.51%) is better than 87.88% of its industry peers.
- CPH's Operating Margin has declined in the last couple of years.
- CPH's Gross Margin of 74.32% is amongst the best of the industry. CPH outperforms 93.94% of its industry peers.
- In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CPH is destroying value.
- The number of shares outstanding for CPH has been increased compared to 1 year ago.
- CPH has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, CPH has a worse debt to assets ratio.
2.2 Solvency
- CPH has an Altman-Z score of 6.38. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of CPH (6.38) is better than 90.91% of its industry peers.
- CPH has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
- CPH has a Debt to FCF ratio of 0.45. This is amongst the best in the industry. CPH outperforms 93.94% of its industry peers.
- CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
- CPH has a Debt to Equity ratio of 0.12. This is in the better half of the industry: CPH outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.38 |
ROIC/WACC0.85
WACC8.56%
2.3 Liquidity
- CPH has a Current Ratio of 1.30. This is a normal value and indicates that CPH is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.30, CPH is doing worse than 66.67% of the companies in the same industry.
- CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
- CPH has a Quick ratio (0.98) which is in line with its industry peers.
- CPH does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
- CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
- CPH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.97% yearly.
- CPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.17%.
- Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.25% on average per year.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
- Based on estimates for the next years, CPH will show a very strong growth in Earnings Per Share. The EPS will grow by 20.66% on average per year.
- Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 27.91% on average per year.
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.21, the valuation of CPH can be described as correct.
- Based on the Price/Earnings ratio, CPH is valued cheaper than 81.82% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.06. CPH is valued slightly cheaper when compared to this.
- CPH is valuated quite expensively with a Price/Forward Earnings ratio of 27.22.
- Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.86, CPH is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.21 | ||
| Fwd PE | 27.22 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH is on the same level as its industry peers.
- CPH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. CPH is cheaper than 78.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.09 | ||
| EV/EBITDA | 14.06 |
4.3 Compensation for Growth
- CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of CPH may justify a higher PE ratio.
- A more expensive valuation may be justified as CPH's earnings are expected to grow with 20.66% in the coming years.
PEG (NY)0.31
PEG (5Y)1.25
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
- No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (2/9/2026, 7:00:00 PM)
14.59
+0.19 (+1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-16 2026-03-16
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap370.15M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target19.58 (34.2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)6.52%
PT rev (3m)7.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0.72%
EPS NY rev (3m)10.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.21 | ||
| Fwd PE | 27.22 | ||
| P/S | 5.43 | ||
| P/FCF | 9.09 | ||
| P/OCF | 9.07 | ||
| P/B | 2.39 | ||
| P/tB | 11.91 | ||
| EV/EBITDA | 14.06 |
EPS(TTM)0.9
EY6.17%
EPS(NY)0.54
Fwd EY3.67%
FCF(TTM)1.6
FCFY11%
OCF(TTM)1.61
OCFY11.03%
SpS2.68
BVpS6.11
TBVpS1.23
PEG (NY)0.31
PEG (5Y)1.25
Graham Number11.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.38 |
F-Score7
WACC8.56%
ROIC/WACC0.85
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y52.6%
EPS Next 2Y-7.46%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year142.1%
EBIT Next 3Y51.2%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.21 and the Price/Book (PB) ratio is 2.39.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.